Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study

Abstract

This epidemiological study of a small, but clinically well-annotated patient cohort fails to support the assumption that the strong increase of bevacizumab use since 2010 improved survival in glioblastoma although clinical benefit associated with decreased steroid use may have been achieved.